Success Stories: Transforming Cancer Care Through Metabolomics: NIW Approved for Biomedical Engineering PhD Candidate in Just 1 Month, 18 Days

Client’s Testimonial:

“NAILG is extremely professional and very supportive throughout the whole journey. I am very grateful for the extraordinary attorneys who allowed my dreams to come true. I will definitely work with them again on EB1A application and recommend them to my friends!”

On May 28^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a PhD Candidate in the Field of Biomedical Engineering (Approval Notice).

General Field: Biomedical Engineering

Position at the Time of Case Filing: PhD Candidate

Country of Origin: China

State of Residence at the Time of Filing: Michigan

Approval Notice Date: May 28^th, 2025

Processing Time: 1 month, 18 days (Premium Processing Requested)

Case Summary:

Cancer doesn’t wait, and researchers like our client aren’t standing still. With over 35 million new cases projected globally by 2050, the demand for highly targeted, effective therapies has never been more critical. A biomedical engineer working at the intersection of metabolomics and oncology is answering that call by exploring how metabolic interactions within the tumor microenvironment can unlock new, personalized treatment strategies.

Her proposed endeavor builds on years of focused research into cancer metabolic reprogramming and tumor crosstalk. By applying high-resolution metabolomic profiling tools and integrating them with robust experimental validation methods, she is helping to lay the groundwork for therapies that aren’t just reactive, but predictive and precisely tailored. The ultimate goal? Accelerate clinical translation and improve survival rates for some of the most challenging cancer types.

This kind of work doesn’t go unnoticed. Our client’s research has been supported by a powerful network of institutions, including the National Cancer Institute, the National Institutes of Health, the Breast Cancer Research Foundation, the Cancer Prevention and Research Institute of Texas, the American Cancer Society, the Ovarian Cancer Research Alliance, the Cholangiocarcinoma Foundation, and the National Science Foundation. Her growing publication record – 6 peer-reviewed journal articles (1 first-authored) and 5 conference abstracts (2 first-authored), with 139 total citations – underscores her rising influence in this field.

One leading expert captured her impact succinctly:

“To conclude, [client]’s remarkable research in metabolic-targeted cancer therapies demonstrates her exceptional expertise in addressing complex biomedical challenges. Through her innovative integration of untargeted global metabolomic profiling with precise experimental validation approaches, [client] strengthens U.S. healthcare capabilities and biotechnology advancement, establishing herself as an invaluable asset to the nation’s medical research infrastructure and global leadership in precision oncology innovation.”

When our client sought assistance from the North America Immigration Law Group (NAILG) to pursue a National Interest Waiver, the strength of her scientific record was clear. But it was NAILG’s deep understanding of how to connect that record to U.S. national interests, especially in public health, clinical innovation, and biotech competitiveness, that helped secure her petition approval. With this milestone behind her, our client is poised to continue pushing the boundaries of cancer research in a way that serves both patients and the national scientific agenda.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.